Pharmacie Principale Revenue and Competitors
Estimated Revenue & Valuation
- Pharmacie Principale's estimated annual revenue is currently $23.8M per year.
- Pharmacie Principale's estimated revenue per employee is $270,000
Employee Data
- Pharmacie Principale has 88 Employees.
- Pharmacie Principale grew their employee count by -2% last year.
Pharmacie Principale's People
Name | Title | Email/Phone |
---|
Pharmacie Principale Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $66.2M | 223 | 20% | N/A | N/A |
#2 | $7.3M | 34 | 6% | N/A | N/A |
#3 | $217.7M | 645 | 27% | N/A | N/A |
#4 | $129.6M | 384 | 10% | N/A | N/A |
#5 | $15.1M | 62 | 22% | N/A | N/A |
#6 | $42.8M | 144 | 15% | N/A | N/A |
#7 | $110.8M | 323 | 13% | $117M | N/A |
#8 | $103.2M | 301 | 2% | $440.7K | N/A |
#9 | $107.3M | 318 | 10% | N/A | N/A |
#10 | $46.9M | 158 | 34% | N/A | N/A |
What Is Pharmacie Principale?
Pharmacie Principale S.A. is a professions médicales company based out of Geneva, Geneva, Switzerland.
keywords:N/AN/A
Total Funding
88
Number of Employees
$23.8M
Revenue (est)
-2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Pharmacie Principale News
2022-04-19 - Des comprimés contre la COVID-19 disponibles en pharmacie ...
: Les deux principales contre-indications sont les problèmes de foie et de reins sévères. Le principal enjeu, c'est que le Paxlovid interagit...
2022-04-13 - Médecins et pharmacies de garde du dimanche 10 avril
Nanteuil-en-Vallée: Pharmacie Fouché, 1, rue du Moulin de la Tâche, 05.45.31.82.68. Roullet-Saint-Estèphe: Pharmacie Principale, 22,...
2022-03-30 - De garde ce dimanche 27 mars
Pharmacie principale Prat-Gaubert, 26 rue Vincent-Mir, à Saint-Lary-Soulan (jusqu'à lundi 9 heures). Tél. 05 62 39 40 25 ; fax : 05 62 40 03...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 88 | 31% | N/A |
#2 | N/A | 90 | 11% | N/A |
#3 | N/A | 91 | 52% | N/A |
#4 | N/A | 91 | 52% | N/A |
#5 | $15M | 91 | 0% | N/A |